Table 1.
Characteristics of patients of with salivary gland carcinomas (n = 167) with respect to PD-L1 expression in tumor cells and tumor-infiltrating immune cells.
| PD-L1 in tumor cells | PD-L1 in tumor-infiltrating immune cells | PD-L1 in tumor and tumor-infiltrating immune cells | |||||||
|---|---|---|---|---|---|---|---|---|---|
| positive (n = 28, 16.8%) | negative (n = 139, 83.2%) | p value | positive (n = 34, 20.4%) | negative (n = 133, 79.6%) | p value | positive (n = 17,10.2%) | negative (n = 150, 89.8%) | p value | |
| Age | 61.5 ± 22.7 years | 56.4 ± 18.1 years | 0.269 | 63.1 ± 20.6 years | 55.7 ± 18.3 years | 0.063 | 64.5 ± 24.7 years | 56.4 ± 18.1 years | 0.208 |
| Gender (F/M) | 15/13 (53.6/46.4%) | 68/71 (48.9/51.1%) | 0.653 | 16/18 (47.1/52.9%) | 67/66 (50.4/49.6%) | 0.730 | 9/8 (52.9/47.1%) | 74/76 (49.3/51.7%) | 0.804 |
| T classification | 0.178 | 0.714 | 0.376 | ||||||
| T1 | 3 (10.7%) | 32 (23.0%) | 7 (20.6%) | 28 (21.0%) | 2 (11.8%) | 33 (22.0%) | |||
| T2 | 12 (42.9%) | 29 (20.9%) | 12 (35.3%) | 29 (21.8%) | 8 (47.1%) | 33 (22.0%) | |||
| T3 | 8 (28.6%) | 33 (23.7%) | 11 (32.4%) | 30 (22.6%) | 4 (23.5%) | 37 (24.7%) | |||
| T4a | 3 (10.7%) | 17 (12.2%) | 3 (8.8%) | 17 (12.8%) | 3 (17.6%) | 17 (11.3%) | |||
| T4b | 0 | 3 (2.2%) | 1 (2.9%) | 2 (1.5%) | 0 | 3 (2.0%) | |||
| Tx | 2 (7.1%) | 25 (18.0%) | 0 | 27 (20.3%) | 0 | 27 (18.0%) | |||
| N classification | 0.894 | 0.723 | 0.681 | ||||||
| N0 | 11 (39.3%) | 53 (38.1%) | 14 (41.2%) | 50 (37.6%) | 6 (35.3%) | 58 (38.6%) | |||
| N1 | 1 (3.6%) | 6 (4.3%) | 2 (5.9%) | 5 (3.8%) | 1 (5.9%) | 6 (4.0%) | |||
| N2a | 2 (7.1%) | 6 (4.3%) | 3 (8.9%) | 5 (3.8%) | 1 (5.9%) | 7 (4.7%) | |||
| N2b | 6 (21.4%) | 21 (15.2%) | 8 (23.5%) | 19 (14.2%) | 5 (29.4%) | 22 (14.7%) | |||
| Nx | 8 (28.6%) | 53 (38.1%) | 7 (20.5%) | 54 (40.6%) | 4 (23.5%) | 57 (38.0%) | |||
| M classification | 0.073 | 0.904 | 0.543 | ||||||
| M0 | 18 (64.3%) | 111 (79.9%) | 26 (76.5%) | 103 (77.4%) | 12 (70.6%) | 117 (78.0%) | |||
| M1 | 10 (35.7%) | 28 (20.1%) | 8 (23.5%) | 30 (22.6%) | 5 (29.4%) | 33 (22.0%) | |||
| Mx | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Grading | 0.035* | 0.058 | 0.031* | ||||||
| G1 | 6 (21.4%) | 56 (40.3%) | 11 (32.4%) | 51 (38.3%) | 2 (11.8%) | 60 (40.0%) | |||
| G2 | 4 (14.3%) | 29 (20.9%) | 3 (8.8%) | 30 (22.6%) | 3 (17.6%) | 30 (20.0%) | |||
| G3 | 18 (64.3%) | 52 (37.4%) | 20 (58.8%) | 50 (37.6%) | 12 (70.6%) | 58 (38.7%) | |||
| Gx | 0 | 2 (1.4%) | 0 | 2 (1.5%) | 0 | 2 (1.3%) | |||
| Perineural invasvion | 0.096 | 0.054 | 0.305 | ||||||
| Pn0 | 18 (64.3%) | 63 (45.3%) | 22 (64.7%) | 59 (44.3%) | 11 (64.7%) | 70 (46.7%) | |||
| Pn1 | 10 (35.7%) | 71 (51.1%) | 12 (35.3%) | 69 (51.9%) | 6 (25.3%) | 75 (50.0%) | |||
| Pnx | 0 | 5 (3.6%) | 0 | 5 (3.8%) | 0 | 5 (3.3%) | |||
| Lymphatic vessel invasion | 0.515 | 0.230 | 0.404 | ||||||
| L0 | 19 (67.9%) | 99 (71.2%) | 22 (64.7%) | 96 (72.2%) | 11 (64.7%) | 107 (71.4%) | |||
| L1 | 9 (32.1%) | 35 (25.2%) | 12 (35.3%) | 32 (24.0%) | 6 (35.3%) | 38 (25.3%) | |||
| Lx | 0 | 5 (3.6%) | 0 | 5 (3.8%) | 0 | 5 (3.3%) | |||
| Blood vessel invasion | 0.056 | 0.891 | 1.000 | ||||||
| V0 | 22 (78.6%) | 122 (87.8%) | 30 (88.2%) | 114 (85.7%) | 15 (88.2%) | 129 (86.0%) | |||
| V1 | 6 (21.4%) | 12 (8.6%) | 4 (11.8%) | 14 (10.5%) | 2 (11.8%) | 16 (10.7%) | |||
| Vx | 0 | 5 (3.6%) | 0 | 5 (3.8%) | 0 | 5 (3.3%) | |||
Chi-square test: A p-value < 0.05 is considered significant.